Daclaxen 60 mg (Daclatasvir) 28 Tablets

Daclaxen 60 mg, containing the active pharmaceutical ingredient Daclatasvir, is a potent direct-acting antiviral (DAA) and the generic equivalent of the innovator brand Daklinza. It is classified as an NS5A replication complex inhibitor. In the management of chronic Hepatitis C virus (HCV) infection, Daclaxen is utilized as a foundational component of combination therapy, often alongside other antivirals like Sofosbuvir. By specifically targeting the viral protein responsible for RNA replication and assembly, Daclatasvir helps achieve a sustained virologic response (SVR), effectively clearing the virus from the patient’s system.

Daclaxen 60 mg Prescribing information & Clinical Guide

What are the primary clinical indications for Daclaxen 60 mg?

Daclatasvir is indicated for the treatment of chronic Hepatitis C virus (HCV) infection in adults. According to guidelines from the FDA and EMA:

• Combination Therapy: It is used in combination with other agents, most commonly Sofosbuvir, with or without Ribavirin.
• Genotype Coverage: It is effective across multiple genotypes, particularly Genotypes 1 and 3.
• Complex Cases: It is utilized in patients with compensated and decompensated cirrhosis and in those whose infection has returned after liver transplantation.

How does Daclatasvir target the virus at a molecular level?

HCV requires a non-structural protein called NS5A to replicate its genetic material and assemble new viral particles. Without functional NS5A, the virus cannot reproduce or spread to healthy liver cells.

Daclatasvir is a highly selective inhibitor of the HCV NS5A protein. It binds to the N-terminus of the protein, causing a conformational change that disrupts the assembly of the replication complex. This targeted inhibition results in a rapid decline in viral RNA levels and prevents the formation of new infectious virions.

What is the recommended dosage and administration?

The administration of Daclaxen follows a strictly defined daily schedule to ensure maximum viral suppression:

• Standard Dosage: The recommended dose is 60 mg taken orally once daily.
• Administration: It can be taken with or without food.
• Drug Interactions (Dose Adjustment): Because it interacts with the CYP3A enzyme, the dose may be reduced to 30 mg (if taken with strong CYP3A inhibitors) or increased to 90 mg (if taken with moderate CYP3A inducers) under clinical supervision.

Consistency: The tablet must be swallowed whole. Do not crush or chew it. Treatment duration is typically 12 or 24 weeks depending on the genotype and the presence of cirrhosis.

What does the clinical evidence show regarding its effectiveness?

The efficacy of Daclatasvir is grounded in the ALLY trial series, documented on ClinicalTrials.gov and published in the New England Journal of Medicine (NEJM):

• ALLY-3 Trial (Genotype 3): In patients with Genotype 3 infection treated with Daclatasvir and Sofosbuvir for 12 weeks, the SVR12 (cure rate) was 90% in treatment-naïve patients and 86% in treatment-experienced patients.
• ALLY-1 Trial (Advanced Disease): Demonstrated high cure rates even in patients with advanced cirrhosis (83-94%) and those post-transplant (94-95%).

Safety, Side Effects, and Monitoring

What are the potential side effects associated with treatment?

Daclatasvir is generally well-tolerated when used alone, but since it is always used in combination, side effects often reflect the broader regimen. Based on reporting from the FDA and Medscape:

• Common Effects: Headache, fatigue, nausea, and diarrhea are frequently reported (occurring in ≥10% of patients).
• Combination with Ribavirin: When Ribavirin is added, patients may also experience anemia, insomnia, and rash.
• Bradycardia Risk: A serious risk of symptomatic bradycardia (slow heart rate) exists when Daclatasvir and Sofosbuvir are taken alongside the heart medication Amiodarone. This combination should be avoided if possible.

Are there significant clinical risks requiring monitoring?

• Hepatitis B Reactivation: Before starting, patients must be screened for Hepatitis B (HBV). DAAs can cause a dormant HBV infection to become active again, leading to serious liver problems.
• Liver Function: Routine monitoring of liver enzymes is recommended during the first several weeks, particularly in patients with pre-existing cirrhosis.

Storage Data and Environmental Stability

Daclaxen 60 mg tablets are stable at room temperature and do not require cold chain refrigeration.

• Standard Storage: Keep at controlled room temperature, 20°C to 25°C (68°F to 77°F).
• Protection: Store in the original container to protect the tablets from moisture.

Transit Integrity: Certified pharmaceutical exporters utilize climate-controlled logistics to ensure the medication is not subjected to extreme heat during international transit, preserving the drug’s molecular stability.

Manufacturer Quality and Trust

Daclaxen 60 mg is manufactured by Everest Pharmaceuticals. In the sphere of global health, manufacturing transparency is the bedrock of patient trust. Everest Pharmaceuticals operates under strict WHO GMP (World Health Organization Good Manufacturing Practices) and ICH guidelines. Their facility utilizes high-precision technology and rigorous batch-testing to ensure that every tablet is bioequivalent to the innovator brand (Daklinza), providing the same purity and clinical efficacy.

Global Access to Daclatasvir

Accessing specialized antiviral therapy internationally is a legally governed process. Patients can access Daclaxen 60 mg through verified pharmaceutical exporters under “Personal Use Importation” or “Named Patient” rules.

A valid prescription from a licensed physician or hepatologist is a mandatory requirement. Most national health ministries permit the legal importation of life-saving medicines if they are not available locally or if the generic version is more accessible. This process ensures the patient receives the necessary treatment while remaining under professional medical supervision.

Frequently Asked Questions (FAQs)

Is Daclaxen 60 mg clinically equivalent to Daklinza?

Yes. Daclaxen contains Daclatasvir, the identical active pharmaceutical ingredient as Daklinza. Manufactured under WHO GMP standards, it is clinically bioequivalent, ensuring that it inhibits the NS5A protein with the same potency and mechanism as the original version.

Can Daclaxen be taken as a standalone treatment for Hepatitis C?

No. Daclatasvir must always be used in combination with other antiviral medications (like Sofosbuvir). Using it alone can lead to the virus developing resistance, making the infection harder to treat.

What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember if it is within 20 hours of the scheduled time. If more than 20 hours have passed, skip the missed dose and take the next dose at the regular time. Never “double up” to catch up.

Why is it important to check for Hepatitis B before starting?

Direct-acting antivirals like Daclaxen can sometimes cause the Hepatitis B virus to become active again if you have previously been exposed to it. This can lead to sudden, severe liver inflammation, so screening is a mandatory safety step.

How do I know if the treatment is working?

Your doctor will perform blood tests to measure the “viral load” (the amount of virus in your blood). Usually, the virus becomes undetectable within the first few weeks of treatment. A successful cure is confirmed 12 weeks after the treatment is finished (SVR12).